Mutation That Induces High Blood Pressure in Women Linked to Increased Heart Attack Risk
|
By LabMedica International staff writers Posted on 05 Aug 2014 |
A mutation in women in the G-protein coupled estrogen receptor 30 (GPER) gene generates a receptor with reduced activity that induces high blood pressure, the single biggest risk factor for heart attack and stroke.
The GPER gene is a member of the G-protein coupled receptor 1 family and encodes an integral membrane protein with high affinity for estrogen that localizes to the endoplasmic reticulum. The protein binds estrogen, resulting in intracellular calcium mobilization and synthesis of phosphatidylinositol 3,4,5-trisphosphate in the nucleus. This protein plays a role in the rapid nongenomic signaling events widely observed following stimulation of cells and tissues with estrogen.
Investigators at the Schulich School of Medicine & Dentistry (London, ON, Canada) found that a common missense genetic variant of GPER, P16L GPER, was poorly functional when expressed in vascular smooth muscle cells. Furthermore, females—but not males—carrying this genetic variant had increased blood pressure and had a higher allelic prevalence in a highly selected population of hard-to-treat hypertensive patients.
"This is one step in understanding the effects of estrogen on heart disease, and understanding why some women are more prone to heart attack and stroke than others," said senior author Dr. Ross Feldman, professor of medicine and physiology/pharmacology at the Schulich School of Medicine & Dentistry. "Our work is a step forward in developing approaches to treating heart disease in this under-appreciated group of patients."
The study was published in the July 21, 2014, online edition of the British Journal of Clinical Pharmacology.
Related Links:
Schulich School of Medicine & Dentistry
The GPER gene is a member of the G-protein coupled receptor 1 family and encodes an integral membrane protein with high affinity for estrogen that localizes to the endoplasmic reticulum. The protein binds estrogen, resulting in intracellular calcium mobilization and synthesis of phosphatidylinositol 3,4,5-trisphosphate in the nucleus. This protein plays a role in the rapid nongenomic signaling events widely observed following stimulation of cells and tissues with estrogen.
Investigators at the Schulich School of Medicine & Dentistry (London, ON, Canada) found that a common missense genetic variant of GPER, P16L GPER, was poorly functional when expressed in vascular smooth muscle cells. Furthermore, females—but not males—carrying this genetic variant had increased blood pressure and had a higher allelic prevalence in a highly selected population of hard-to-treat hypertensive patients.
"This is one step in understanding the effects of estrogen on heart disease, and understanding why some women are more prone to heart attack and stroke than others," said senior author Dr. Ross Feldman, professor of medicine and physiology/pharmacology at the Schulich School of Medicine & Dentistry. "Our work is a step forward in developing approaches to treating heart disease in this under-appreciated group of patients."
The study was published in the July 21, 2014, online edition of the British Journal of Clinical Pharmacology.
Related Links:
Schulich School of Medicine & Dentistry
Latest Pathology News
- Rapid Stool Test Could Help Pinpoint IBD Diagnosis
- AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery
- Deep Learning–Based Method Improves Cancer Diagnosis
- ADLM Updates Expert Guidance on Urine Drug Testing for Patients in Emergency Departments
- New Age-Based Blood Test Thresholds to Catch Ovarian Cancer Earlier
- Genetics and AI Improve Diagnosis of Aortic Stenosis
- AI Tool Simultaneously Identifies Genetic Mutations and Disease Type
- Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups
- Tumor Signals in Saliva and Blood Enable Non-Invasive Monitoring of Head and Neck Cancer
- Common Health Issues Can Influence New Blood Tests for Alzheimer’s Disease
- Blood Test Formula Identifies Chronic Liver Disease Patients with Higher Cancer Risk
- Tunable Cell-Sorting Device Holds Potential for Multiple Biomedical Applications
- AI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
- AI Tool Rapidly Analyzes Complex Cancer Images for Personalized Treatment
- Diagnostic Technology Performs Rapid Biofluid Analysis Using Single Droplet
- Novel Technology Tracks Hidden Cancer Cells Faster
Channels
Clinical Chemistry
view channel
Blood Test Could Predict and Identify Early Relapses in Myeloma Patients
Multiple myeloma is an incurable cancer of the bone marrow, and while many patients now live for more than a decade after diagnosis, a significant proportion relapse much earlier with poor outcomes.... Read more
Compact Raman Imaging System Detects Subtle Tumor Signals
Accurate cancer diagnosis often depends on labor-intensive tissue staining and expert pathological review, which can delay results and limit access to rapid screening. These conventional methods also make... Read moreMolecular Diagnostics
view channel
Genetic Test Could Detect Predisposition to Pancreatic Cancer
Pancreatic ductal adenocarcinoma is one of the deadliest cancers, largely because it is usually diagnosed at an advanced stage when treatment options are limited. The lack of effective population screening... Read more
Blood Test Predicts Crohn’s Disease Years Before Symptoms Appear
Crohn’s disease is a chronic inflammatory disorder of the gastrointestinal tract that causes persistent digestive symptoms, pain, and fatigue, often leading to lifelong treatment. Incidence rates are rising... Read moreHematology
view channel
AI Algorithm Effectively Distinguishes Alpha Thalassemia Subtypes
Alpha thalassemia affects millions of people worldwide and is especially common in regions such as Southeast Asia, where carrier rates can reach extremely high levels. While the condition can have significant... Read more
MRD Tests Could Predict Survival in Leukemia Patients
Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read moreImmunology
view channel
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
New Test Measures How Effectively Antibiotics Kill Bacteria
Antibiotics are typically evaluated by how well they inhibit bacterial growth in laboratory tests, but growth inhibition does not always mean the bacteria are actually killed. Some pathogens can survive... Read more
New Antimicrobial Stewardship Standards for TB Care to Optimize Diagnostics
Antibiotic resistance is rising worldwide, threatening the effectiveness of treatments for major infectious diseases, including tuberculosis (TB). Resistance to key TB drugs, such as bedaquiline, is of... Read moreTechnology
view channel
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read more
AI-Generated Sensors Open New Paths for Early Cancer Detection
Cancers are far easier to treat when detected early, yet many tumors remain invisible until they are advanced or have recurred after surgery. Early-stage disease often produces signals that are too weak... Read moreIndustry
view channel
WHX Labs Dubai to Gather Global Experts in Antimicrobial Resistance at Inaugural AMR Leaders’ Summit
World Health Expo (WHX) Labs in Dubai (formerly Medlab Middle East), which will be held at Dubai World Trade Centre from 10-13 February, will address the growing global threat of antimicrobial resistance... Read more







